Caught on camera: Quack impersonates medical intern at PGIMS Rohtak

Rohtak: In a disturbing incident that has raised serious concerns about patient safety, a young man holding only a diploma in patient care assistance was caught treating patients at the Post-Graduate Institute of Medical Sciences (PGIMS) in Rohtak, pretending to be his friend, who is a medical intern at the hospital. 

He was seen roaming around the OPD ward and even the trauma centre, wearing a white coat with a stethoscope around his neck, and attending to patients. His behaviour and way of speaking raised suspicion among the security guards. When he was asked for his ID card, he was unable to show it.

Also read- Quack poses as Radiologist for 2 years using Rs 50 lakh fake degree

After confirming that he was not a doctor, the guards took him out of the premises after taking the stethoscope from him. A video of him treating patients and getting escorted outside the hospital by the security has gone viral on social media.

As per the HT media report, the accused has been identified as Sahad from Nizampur Majra village in Sonepat. Sahad was impersonating his friend Krishan Gehlawat, who is currently doing a one-year internship at PGIMS after completing his MBBS from the United Kingdom. 

The fake doctor was caught at the orthopaedics department during a routine security check when he was asked for his name. However, while going through the duty roster, the security guards did not find his name. Therefore, they asked him to show his ID card, which he failed to do.

During questioning, Sahad reportedly told authorities that he had a diploma in patient care assistance and claimed he was asked by Krishan to fill in for him. 

Dr Rohit, the security in-charge at PGIMS, confirmed the arrest and said that Sahad was immediately handed over to the police. He also said that efforts are underway to nab Krishan. “Sahad will be produced in court on Friday. A thorough investigation is being conducted,” he said.

Medical Dialogues recently reported that a senior contractual doctor who worked in the ICU ward of V N Desai Hospital, Santacruz, for nearly two years, was recently found to be a fake doctor and unregistered with the Maharashtra Medical Council (MMC).

Also read- Fake Doctor Found Working at Mumbai Hospital ICU for 2 years

Powered by WPeMatico

Exercise linked to decreased mortality, heart events in those with new type 2 diabetes but no previous heart disease

New research to be presented at this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that among people recently diagnosed with type 2 diabetes and no previous cardiovascular disease, a clear association exists between a person’s self-reported physical activity and their risk of all-cause mortality and major adverse cardiac events (MACE), which includes heart attacks and strokes.

Powered by WPeMatico

Exercise linked to decreased mortality, heart events in those with new type 2 diabetes but no previous heart disease

New research to be presented at this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that among people recently diagnosed with type 2 diabetes and no previous cardiovascular disease, a clear association exists between a person’s self-reported physical activity and their risk of all-cause mortality and major adverse cardiac events (MACE), which includes heart attacks and strokes.

Powered by WPeMatico

Genetic testing reduces risks from chemotherapy for gastrointestinal cancer patients

For some patients with gastrointestinal (GI) cancers like colorectal and pancreatic cancer, chemotherapy can cause severe, sometimes life-threatening side effects in those who carry certain genetic variants that can impact how their bodies process the drugs used to treat their disease.

Powered by WPeMatico

Genetic testing reduces risks from chemotherapy for gastrointestinal cancer patients

For some patients with gastrointestinal (GI) cancers like colorectal and pancreatic cancer, chemotherapy can cause severe, sometimes life-threatening side effects in those who carry certain genetic variants that can impact how their bodies process the drugs used to treat their disease.

Powered by WPeMatico

Flea-borne typhus infections are on the rise in Southern California: How to protect yourself and your pets

Pet owners, beware: Flea-borne typhus is on the rise in parts of Southern California.

Powered by WPeMatico

Flea-borne typhus infections are on the rise in Southern California: How to protect yourself and your pets

Pet owners, beware: Flea-borne typhus is on the rise in parts of Southern California.

Powered by WPeMatico

RFK Jr. is wrong about mRNA vaccines: A scientist explains how they make COVID less deadly

US health secretary Robert F. Kennedy Jr. has announced he is canceling US $500 million (£374 million) of research into mRNA vaccines, citing unproven concerns about their safety and long-term effects.

Powered by WPeMatico

National study urges expanded vaccine screening in emergency departments

About 49% of people are unaware of one or more vaccines recommended for them. Further, 86% have not received one or more of these vaccines.

Powered by WPeMatico

FDA Approves Inclisiran as First-Line LDL-C Treatment Without Statins

The FDA has approved inclisiran (Leqvio) for first-line use in lowering LDL cholesterol, even without combining it with statins, according to Novartis.

The FDA proactively requested the label update based on the robust LDL-C lowering data for PCSK9-targeting therapies.

“This first-line label update reinforces Leqvio’s proven ability to effectively lower LDL-C, a critical risk factor for heart disease,” said Victor Bultó, President, US, Novartis. “With this new indication enabling Leqvio’s use as monotherapy along with diet and exercise, we now have the potential to help even more patients achieve their LDL-C lowering goals earlier in their treatment journey.”

With its twice-yearly, health care provider-administered dosing, Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainment. This is a critical unmet need, as up to 80% of ASCVD patients in the US struggle to reach the LDL-C guideline-recommended target of <70 mg/dL. This need is heightened by the latest 2025 ACC/AHA Joint Committee Clinical Practice Guideline for the Management of Patients with Acute Coronary Syndromes, which recommends more aggressive treatment to achieve LDL-C targets.

The updated label removes the requirement for Leqvio to be used on top of or in combination with statin therapy. Other updates include revising “primary hyperlipidemia” to the more specific term of “hypercholesterolemia” throughout the label, to more accurately focus on LDL-C reduction.

After an initial dose and another at three months.

About Leqvio

Leqvio is an injectable prescription medicine indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics.

About Atherosclerotic Cardiovascular Disease (ASCVD)

Cardiovascular disease (CVD) affects hundreds of millions of people and claims more lives globally than cancer, chronic lung disease and diabetes combined. Around 80% of premature cardiovascular deaths can be prevented by addressing factors that cause or worsen CVD.

ASCVD accounts for 85% of all CV deaths. Its burden in the US is greater than that of any other chronic diseases. ASCVD is caused by the development and growth of plaques in the inner lining of the arteries. The atherosclerotic plaque is mainly composed of low-density lipoprotein cholesterol (LDL-C) that accumulates over time. Cumulative exposure to LDL-C can increase one’s risk of cardiovascular events such as a heart attack or stroke.

Powered by WPeMatico